Nurix Therapeutics (NRIX) CFO sells stock to cover RSU tax withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Nurix Therapeutics, Inc.’s Chief Financial Officer, Hans van Houte, reported routine equity compensation activity and related tax sales. On January 30, 2026, several blocks of restricted stock units (RSUs) converted into common stock at $0 exercise price, including 2,887, 2,000, 3,750 and 2,859 RSUs.
To cover tax withholding from these RSU vestings, the CFO sold 3,588 shares at a weighted average price of $16.5826 and 73 shares at a weighted average price of $17.3717. The filing states these are mandatory “sell to cover” transactions, not discretionary trades. After the transactions, he directly owned 45,427 common shares and 25,725 RSUs.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 3,661 shares ($60,767)
Net Sell
10 txns
Insider
van Houte Hans
Role
Chief Financial Officer
Sold
3,661 shs ($61K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 2,887 | $0.00 | -- |
| Exercise | Restricted Stock Units | 2,000 | $0.00 | -- |
| Exercise | Restricted Stock Units | 3,750 | $0.00 | -- |
| Exercise | Restricted Stock Units | 2,859 | $0.00 | -- |
| Exercise | Common Stock | 2,887 | $0.00 | -- |
| Exercise | Common Stock | 2,000 | $0.00 | -- |
| Exercise | Common Stock | 3,750 | $0.00 | -- |
| Exercise | Common Stock | 2,859 | $0.00 | -- |
| Sale | Common Stock | 3,588 | $16.5826 | $59K |
| Sale | Common Stock | 73 | $17.3717 | $1K |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 40,479 shares (Direct)
Footnotes (1)
- The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $16.33 and the highest price at which shares were sold was $17.32. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Represents the weighted average sale price. The lowest price at which shares were sold was $17.33 and the highest price at which shares were sold was $17.49. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
FAQ
What insider transaction did Nurix Therapeutics (NRIX) disclose for its CFO?
Nurix reported that CFO Hans van Houte had RSUs convert into common stock, then sold a portion of the resulting shares. The sales were solely to cover tax withholding obligations tied to RSU vesting and were mandated by the company’s equity incentive plans.
Why did the Nurix (NRIX) CFO’s Form 4 sales occur on January 30, 2026?
The sales were required to satisfy tax withholding when restricted stock units vested on January 30, 2026. Nurix’s equity incentive plans mandate “sell to cover” transactions for these obligations, so the trades did not represent discretionary selling by the CFO.
What restricted stock unit (RSU) activity did Nurix (NRIX) report for its CFO?
Nurix reported RSU conversions of 2,887, 2,000, 3,750 and 2,859 units into common stock at a $0 exercise price. The RSUs vest in quarterly installments over multi-year periods, provided the CFO continues to provide services on each scheduled vesting date.
How do Nurix Therapeutics (NRIX) RSUs for the CFO vest over time?
The Form 4 explains that certain RSU grants vest quarterly over four years, while others vest quarterly over three years. Initial vesting dates include April 30, 2022, and July 30 of 2023, 2024, and 2025, with continued service required at each vesting date.